Eli Lilly

17 statements across 1 episodes · 6 bullish · 1 bearish · 2 people on the record · first statement Jan 22, 2024 by David Rosenthal · said 19 times in 1 episodes since 2024 · across every show →

Mentions by year

brought up most by David Rosenthal (11), Ben Gilbert (8)

tap a year for its mentions
001012012024episodesmentions
0112024episodes it came up in
00100.52012024episodesmentions per episode
2024 19 mentions in 1 episode

every mention, scene by scene, with the transcript →

Everything said about Eli Lilly, oldest first

Jan 22, 2024 neutral
Assertion Supported
Eli Lilly remains larger than Novo Nordisk by market capitalization
“This moment, this insulin moment, this is what really turbocharges them and makes them into one of, if not the first kind of leading American and international pharmaceutical company, which it still is to this day, still bigger than Nova Nordisk. Although not …”
David Rosenthal Jan 22, 2024 ▶ 16:10 Novo Nordisk (Ozempic) · Acquired
Jan 22, 2024 positive
Assertion Supported
Novo Nordisk's 84% gross margins surpass Microsoft and Google
“Gross margins are better than software. They run about 84%. Lilly is also a very high margin company, running about 80%. For context, Microsoft has a gross margin of 70% and Google is 56%.”
Ben Gilbert Jan 22, 2024 ▶ 2:24:28 Novo Nordisk (Ozempic) · Acquired
Jan 22, 2024
Assertion Supported
Insulin was the first genetically engineered drug in biotech history
“The first drug that they genetically engineered And that started this whole revolution was insulin.”
David Rosenthal Jan 22, 2024 ▶ 1:15:01 Novo Nordisk (Ozempic) · Acquired
Jan 22, 2024
Assertion Supported
Nordisk licensed NPH insulin globally while refusing to license to Novo
“So Nordisk, rather than building up production facilities around the world, what they decide to do is license it back to basically any interested pharma company. So like Eli Lilly back in the States, other companies in Continental Europe. It's the new, widely …”
David Rosenthal Jan 22, 2024 ▶ 49:00 Novo Nordisk (Ozempic) · Acquired
Jan 22, 2024
Assertion Partly supported
Novo Nordisk and Eli Lilly controlled 95% of the insulin market
“So the new combined company has roughly a billion dollars in insulin revenue and 50%, five zero percent global market share with Eli Lilly just behind at 45% and host at five percent.”
David Rosenthal Jan 22, 2024 ▶ 1:33:27 Novo Nordisk (Ozempic) · Acquired
Jan 22, 2024 positive
Assertion Supported
Eli Lilly's Byetta became the first GLP-1 drug on market
“Eli Lilly develops it into Bayetta, and Bayetta hits the market in 2005. It's FDA approved, and it works. It's not poisonous. It doesn't kill people. And it is the world's first GLP-I analog to come to market.”
David Rosenthal Jan 22, 2024 ▶ 1:54:11 Novo Nordisk (Ozempic) · Acquired
Jan 22, 2024
Assertion Partly supported
Novo Nordisk derives 85% of revenue from metabolic disorders
“85% of their revenue is dedicated to metabolic disorders. They are the second largest market cap pharma, second only to Eli Lilly.”
Ben Gilbert Jan 22, 2024 ▶ 2:56:52 Novo Nordisk (Ozempic) · Acquired
Jan 22, 2024 neutral
Assertion Supported
Novo Nordisk, Eli Lilly, and Sanofi control the entire insulin market
“Sanofi today, yeah, the three of those companies are essentially the entire insulin market.”
Ben Gilbert Jan 22, 2024 ▶ 1:20:31 Novo Nordisk (Ozempic) · Acquired
Jan 22, 2024 positive
Assertion Supported
Eli Lilly traded manufacturing improvements for brand rights in early deal
“The other interesting thing to note about the Eli Lilly license, David, which I thought was really clever, is it's a one-year exclusive license where there's two conditions, and the conditions are a trade. One, Eli Lilly has to report back any advances that th…”
Ben Gilbert Jan 22, 2024 ▶ 15:18 Novo Nordisk (Ozempic) · Acquired
Jan 22, 2024 bullish
Prediction Not checkable as stated
Massive GLP-1 demand will enable multiple pharma hits like insulin
“I think this is going to be like insulin all over again, where there's just going to be a series of product improvements and companies will drive innovation and increase supply. I mean, the demand is so huge out there that Monroe can be a huge hit. Ozempic and…”
David Rosenthal Jan 22, 2024 ▶ 2:36:13 Novo Nordisk (Ozempic) · Acquired
Jan 22, 2024 positive
Assertion Supported
Clinical studies show Mounjaro produces more weight loss than Ozempic
“The studies show Manjaro helps you lose more weight and has a very similar mechanism plus another mechanism that together work, but like, most people don't know that.”
Ben Gilbert Jan 22, 2024 ▶ 2:49:53 Novo Nordisk (Ozempic) · Acquired
Jan 22, 2024 negative
Assertion Supported
Eli Lilly claimed rebates account for 75% of insulin's sticker price
“Eli Lilly has publicly claimed that the cost of these discounts and rebates accounted for 75% of the sticker price of insulin.”
Ben Gilbert Jan 22, 2024 ▶ 1:30:33 Novo Nordisk (Ozempic) · Acquired
Jan 22, 2024 neutral
Assertion Supported
The University of Toronto gave Eli Lilly an exclusive insulin license
“Is they license production and development rights to a large American drug company based in Indiana, Eli Lilly. And they give Eli Lilly a one-year exclusive development license to try and mass produce this substance.”
David Rosenthal Jan 22, 2024 ▶ 13:16 Novo Nordisk (Ozempic) · Acquired
Jan 22, 2024 neutral
Assertion Supported
Eli Lilly, Novo, and Nordisk dominated global insulin sales in 1980
“Novo's annual global insulin sales, this is Novo, they're still much larger. They're about a hundred million dollars annually. And Nordisk's are about thirty million annually. That makes them the number two and number four producers in the world by market shar…”
David Rosenthal Jan 22, 2024 ▶ 1:08:00 Novo Nordisk (Ozempic) · Acquired
Jan 22, 2024 bullish
Prediction Not checkable as stated
GLP-1s could surpass Humira and remain defensible for a decade
“So I think, assuming that Novo stays sort of neck and neck with Eli Lilly as they both keep coming out with better and better versions, that this could be the next Humira, or potentially much bigger than Humira. And I think the defensibility is an open questio…”
Ben Gilbert Jan 22, 2024 ▶ 3:35:25 Novo Nordisk (Ozempic) · Acquired
Jan 22, 2024 neutral
Assertion Supported
Eli Lilly's tirzepatide secured diabetes approval in 2022 and obesity approval
“It was approved in the US for diabetes treatment in May, 20, 22, and approval just came recently in November, 20, 23 for official FDA sanctioned weight loss use case under the marketing name Zep bound.”
David Rosenthal Jan 22, 2024 ▶ 2:35:47 Novo Nordisk (Ozempic) · Acquired
Jan 22, 2024
Assertion Supported
Eli Lilly's United States insulin sales grew from $700M to $2.6B
“In 1999, I think it was, Eli Lilly sold seven hundred million dollars of insulin in America. 1999. By 2017, just two of their products sold 2.6 billion dollars in America.”
Ben Gilbert Jan 22, 2024 ▶ 2:44:24 Novo Nordisk (Ozempic) · Acquired
Made with StarZero

Turn any episode into a week of clips.

This entire site, nearly 80 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.